Eli Lilly and Company Company Profile (NYSE:LLY)

Eli Lilly and Company trades on the New York Stock Exchange (NYSE) under the ticker symbol "LLY."

Eli Lilly and Company declared a quarterly dividend on Monday, June 19th. Investors of record on Tuesday, August 15th will be paid a dividend of $0.52 per share on Friday, September 8th. This represents a $2.08 dividend on an annualized basis and a yield of 2.45%. The ex-dividend date is Friday, August 11th. View Eli Lilly and Company's Dividend History.

Eli Lilly and Company (NYSE:LLY) announced its earnings results on Tuesday, April, 25th. The company reported $0.98 earnings per share (EPS) for the quarter, beating the Thomson Reuters' consensus estimate of $0.96 by $0.02. The business had revenue of $5.23 billion for the quarter, compared to analyst estimates of $5.22 billion. Eli Lilly and Company had a net margin of 10.13% and a return on equity of 26.64%. Eli Lilly and Company's revenue was up 7.5% compared to the same quarter last year. During the same quarter in the prior year, the company posted $0.83 earnings per share. View Eli Lilly and Company's Earnings History.

Eli Lilly and Company is scheduled to release their next quarterly earnings announcement on Tuesday, July, 25th 2017. View Earnings Estimates for Eli Lilly and Company.

Eli Lilly and Company updated its FY17 earnings guidance on Tuesday, April, 25th. The company provided earnings per share (EPS) guidance of $4.05-4.15 for the period, compared to the Thomson Reuters consensus estimate of $4.10. The company issued revenue guidance of $21.8-22.3 billion, compared to the consensus revenue estimate of $22.10 billion.

16 equities research analysts have issued 12 month target prices for Eli Lilly and Company's shares. Their predictions range from $73.00 to $100.00. On average, they anticipate Eli Lilly and Company's share price to reach $88.67 in the next year. View Analyst Ratings for Eli Lilly and Company.

Here are some recent quotes from research analysts about Eli Lilly and Company stock:

• 1. According to Zacks Investment Research, "Lilly’s presence across a wide range of therapeutic areas and its animal health business provide support in the face of generic competition. Lilly also expects some established products like Trajenta, Forteo and Humalog to continue doing well. Lilly expects to launch 20 new products between 2014 and 2023, including the launch of at least two new indications/line extensions on an average every year. The stock has risen this year, outperforming the return from the large cap pharma industry. However, Alimta will continue to be impacted by competition. Other headwinds include competition from immuno-oncology agents as well as loss of exclusivity for many drugs in the emerging markets. Meanwhile, the recent high-profile pipeline setbacks are an investor concern. Estimates have risen slightly ahead of the company’s Q2 release. The company has a mixed record of earnings surprises in recent quarters. " (7/17/2017)
• 2. Jefferies Group LLC analysts commented, "Date and time of first dissemination: July 17, 2017, 08:17 ET Date and time of production: July 17, 2017, 08:17 ET Target Price / Valuation Methodology: Mallinckrodt plc – MNK Our discounted cash flow (DCF) analysis leads us to a price target of $87/share for MNK shares. Our DCF considers our estimates through 2027, slowing growth through 2033 and a 10% terminal decline thereafter. In addition, we expect Mallinckrodt’s margin structure to remain somewhat consistent with our 2027 estimates. We estimate a weighted average cost of capital (WACC) of 11.4% which is in line with other companies in Mallinckrodt’s peer set due to the company’s manageable leverage and consistent cash generation potential." (7/13/2017)
• 3. UBS AG analysts commented, "We adjust our model to account for two months of reported IMS Rx data. Key growth drivers such as Trulicity and Taltz have performed better than expected while Basaglar (insulin glargine) was modestly lower than anticipated. Our overall 2017 revenues are largely unchanged as better than expected sales (largely from the Taltz and Trulicity) offset softer than expected sales of other products, and our 2017 EPS of $4.15 remain unchanged. For 2018, our revenues went up ~$70M largely driven by Taltz and we raise our EPS to $4.45 from $4.40." (3/20/2017)

Some companies that are related to Eli Lilly and Company include Merck & Company (MRK), Sanofi (SNY), Novo Nordisk A/S (NVO), GlaxoSmithKline PLC (GSK), Bristol-Myers Squibb Company (BMY), Abbott Laboratories (ABT), Astrazeneca PLC (AZN), GlaxoSmithKline plc (GSK), AstraZeneca plc (AZN), Shire PLC (SHP), Teva Pharmaceutical Industries Limited (TEVA), Dr. Reddy's Laboratories Ltd (RDY), Valeant Pharmaceuticals International (VRX), Patheon NV (PTHN), Taro Pharmaceutical Industries (TARO), Catalent (CTLT), Akorn (AKRX) and Opko Health (OPK).

Eli Lilly and Company's management team includes the folowing people:

• David A. Ricks, Chairman of the Board, President, Chief Executive Officer
• Derica W. Rice, Chief Financial Officer, Executive Vice President - Global Services
• Jan M. Lundberg Ph.D., Executive Vice President - Science and Technology, President - Lilly Research Laboratories
• Melissa Stapleton Barnes, Senior Vice President - Enterprise Risk Management and Chief Ethics and Compliance Officer
• Michael J. Harrington, Senior Vice President, General Counsel
• Stephen F. Fry, Senior Vice President - Human Resources and Diversity
• Enrique A. Conterno, Senior Vice President and President - Lilly Diabetes and President - Lilly USA
• Susan Mahony Ph.D., Senior Vice President and President - Lilly Oncology
• Barton R. Peterson, Senior Vice President - Corporate Affairs and Communications
• Leigh Ann Pusey, Senior Vice President - Corporate Affairs and Communications

Eli Lilly and Company's stock is owned by a number of of institutional and retail investors. Top institutional shareholders include Lilly Endowment Inc. (11.76%), Fisher Asset Management LLC (0.28%), Beutel Goodman & Co Ltd. (0.24%), US Bancorp DE (0.22%), Bank of Montreal Can (0.14%) and Hexavest Inc. (0.13%). Company insiders that own Eli Lilly and Company stock include Alfonso G Zulueta, David A Ricks, Derica W Rice, Donald A Zakrowski, Enrique A Conterno, Jackson P Tai, Lilly Endowment Inc, Maria A Crowe, Melissa S Barnes, Michael J Harrington, R David Hoover, Stephen F Fry and Susan Mahony. View Institutional Ownership Trends for Eli Lilly and Company.

Eli Lilly and Company's stock was sold by a variety of institutional investors in the last quarter, including Lilly Endowment Inc., NN Investment Partners Holdings N.V., Bedrijfstakpensioenfonds Voor DE Media PNO, Hexavest Inc., OLD National Bancorp IN, Exxonmobil Investment Management Inc. TX, Grassi Investment Management and Park National Corp OH. Company insiders that have sold Eli Lilly and Company stock in the last year include Alfonso G Zulueta, Derica W Rice, Donald A Zakrowski, Enrique A Conterno, Lilly Endowment Inc, Maria A Crowe, Melissa S Barnes, Michael J Harrington and Susan Mahony. View Insider Buying and Selling for Eli Lilly and Company.

Eli Lilly and Company's stock was bought by a variety of institutional investors in the last quarter, including Bank of Montreal Can, Fisher Asset Management LLC, Beutel Goodman & Co Ltd., Mn Services Vermogensbeheer B.V., National Pension Service, Atalanta Sosnoff Capital LLC, Handelsbanken Fonder AB and BKD Wealth Advisors LLC. Company insiders that have bought Eli Lilly and Company stock in the last two years include Jackson P Tai and R David Hoover. View Insider Buying and Selling for Eli Lilly and Company.

Shares of Eli Lilly and Company can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

One share of Eli Lilly and Company stock can currently be purchased for approximately $84.75.